Categories
Tags
Abbott Advertising AstraZeneca Barack Obama Biotechnology and Pharmaceuticals Breast cancer Bristol Myers Squibb business Cancer Clinical trial Conditions and Diseases Deal Eli Lilly European Commission European Union FDA Food and Drug Administration Genentech generics GlaxoSmithKline Google GSK HBA Health Health care Johnson & Johnson layoffs Lilly Margaret Hamburg Marketing Merck Novartis Pfizer Pharma Pharmaceutical drug pharmaceutical industry Research and development Roche Sanofi-Aventis Schering Plough social media Twitter U.S. Food and Drug Administration United States Wyeth
Technology News
BioPharm News- Shire Gains European Approval for its Gaucher Disease Treatment
- Mtech Bioprocess Scale-Up Facility to Double in Staff and Size
- ImClone Closes Plant in New Jersey, Consolidating Erbitux Manufacture
- EMA and FDA Seek Applicants for Joint GMP Inspections
- ATMI Expands Bloomington, Minnesota Manufacturing Facility
Clinical Trials News- CRF Health Achieves EXACT ePRO Vendor Certification for Windows Mobile Systems
- ACR Image Metrix Establishes Global Presence
- BioPharm Systems Named to the 2010 Inc. 500|5000 List of Fastest-Growing Companies in the U.S.
- CRF Health Doubles North American Headquarters
- Oracle Completes Acquisition of Phase Forward
Blogroll
-
Meta
Tag Archives: Eli Lilly
Lower Lilly Earnings the Shape of Things to Come
Eli Lilly announced its first quarter financial results on April 19. But even though the company trumpeted a global revenue growth rate of 9 percent—$5.49 billion, compared to Q1 2009’s $5.05 billion—net income fell 5 percent to $1.25 billion.
Part of the blame for that 4 percent difference, the company said, lies with the passage of [...]
Posted in Strategy Also tagged Earnings, Effexor, John Lechleiter, Lipitor, pricing, Seroquel Leave a comment
Merck, Lilly, Pfizer: One for All and All for One
Just a month after Andrew Witty’s announcement that GSK will make more than 13,500 of its malaria compounds available to all, Pfizer, Merck, and Eli Lilly have thrown their do-gooder hats into the ring as well.
Together, the three drug giants will pull together an undisclosed dollar amount in seed funding and create the independent, non-profit [...]
Posted in Strategy Also tagged ACRG, Andrew Witty, Cancer, Diseases & Conditions, Health, Lung cancer, Pfizer 1 Comment
HBA Names Woman of the Year
GSK’s Deirdre Connelly has been named the Healthcare Businesswomen’s Association’s Woman of the Year for 2010. Connelly, who just passed the one-year mark as president of GSK’s North American pharmaceuticals unit, is the 21st woman to win the organization’s “WOTY” award, which comes on the heels of another honor: She was ranked #37 in Fortune’s [...]
Posted in Corporate Responsibility, News, People, leadership Also tagged Deirdre Connelly, GSK, HBA, WOTY Leave a comment
The Trouble with Transparency
Guest blog by Jacky Law
A couple of weeks ago I attended an industry awards dinner and had an interesting conversation with an eminent doctor who shall remain nameless. The doctor in question works in a highly specialized area and frequently talks about her research at conferences around the world. She always travels first-class and has [...]
Posted in Guest Blog, Strategy Also tagged Congress, GlaxoSmithKline, Herb Kohl, Medicine, Member of Parliament, United States Senate Committee on Finance, US Leave a comment

Abbott Shells Out $3.7 Billion for Piramal